Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Anas Gazzah1 SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France

Daniel Barrios Gonzales1 SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France

Antonin Levy1 SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France

Rastislav Bahleda1 SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France

Michel Ducreux2 Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France

Ludovic Lacroix3 Department of Biology, Institut Gustave Roussy, Paris XI University, Villejuif, France

Jean Charles Soria1 SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, FranceCorrespondence[email protected]

show all

Abstract

Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in advanced pancreatic cancer. To highlight the potential interest of this targetable pathway in selected advanced pancreatic cancer patients, we report herein a patient with an activated PI3K mutation who was treated in a phase I trial evaluating a treatment combination including an mTOR inhibitor.

Keywords:

Disclosure

The authors have no conflicts of interest to disclose.

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Information for

Open access

Opportunities

Help and information

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Abstract

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature